1-β-D-arabinofuranosylcytosine-5'-alkylphosphonophosphates and diphosphates: New orally active derivatives of ara-C

Journal of Lipid Research

Volumn 39, Issue 1, 1998, Pages 162-172

  Brachwitz, H ^a   Bergmann, J ^a   Fichtner, I ^a   Thomas, Y ^b   Vollgraf, C ^a   Langen, P ^a   Berdel, W E ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Alkylphospholipids; Antiproliferative activity; ara C derivatives; Calcium; Drug combination; In vitro studies; In vivo studies; Phosphonophosphates

Indexed keywords

ARA CYTIDINE 5' DEXADECYLDIPHOSPHATE; ARA CYTIDINE 5' HEXADECYLPHOSPHONOPHOSPHATE; ARA CYTIDINE 5' OCTADECYLDIPHOSPHATE; ARA CYTIDINE 5' OCTADECYLPHOSPHONOPHOSPHATE; CYTARABINE; CYTARABINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG POTENCY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHATIC LEUKEMIA; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCIUM; CELL DIVISION; CELL LINE; CYTARABINE; FEMALE; HUMANS; LEUKEMIA P388; MICE; MOLECULAR STRUCTURE; PHOSPHOLIPID ETHERS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0031931256     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rustum, M., and R. A. P. Raymakers. (1993). 1-β-Arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol. Ther. 56: 307-321.
2. Ho, D. H. W. 1973. Distribution of kinase and deaminase of 1-β-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res. 33: 2816-2820.
3. Berdel, W. E., S. Danhauser, C. I. Hong, H. D. Schick, A. Reichert, R. Busch, J. Rasteuer, and W. R. Vogler. 1988. Influence of 1-beta-D-arabinofuranosylcytosine conjugates of lipids on the growth and metastasis of Lewis lung carcinoma. Cancer Res. 48: 826-829.
4. Brachwitz, H., P. Langen, and F. Paltauf. 1990. Cytidine-5′-diphosphate-alkylglycerol analogs (CDP-AG) - a new class of cytostatically active phospholipids. Cancer Res. Clin. Oncol. (Supplement) 116: 993.
5. Brachwitz, H., and C. Vollgraf. 1995. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol. Ther. 66: 39-82.
6. Brachwitz, H., U. Lachmann, Y. Thomas, J. Bergmann, W. E. Berdel, and P. Langen. 1996. Synthesis and antiproliferative activity of cytidine-5′-alkylphosphonophosphates and structurally related compounds. Chem. Phys. Lipids. 83: 77-85.
7. Brachwitz, H., Y. Thomas, J. Bergmann, W. E. Berdel, and P. Langen. 1997. New nucleoside-5-alkylphosphonophosphates and related compounds containing 2-deoxycytidine, thymidine and adenosine as nucleoside component. Synthesis and their effects on tumor cell growth in vitro. Chem. Phys. Lipids. 87: 31-39.
8. Skipper, H. E., F. M. Schabel, L. B. Mellet, J. A. Montgomery, L. J. Wilkoff, H. H. Lloyd, and R. W. Brockman. 1970. Cancer Chemother. Rep. Part 1, 54: 431-438.
9. Brachwitz, H., D. Arndt, I. Fichtner, and P. Langen. 1987. Cytostatic activity of synthetic O-alkylglycerolipids. Lipids. 22: 897-903.
10. Brachwitz, H. P. Langen, and C. Vollgraf. 1992. Phosphobzw. Phosphono-(N-acyl)-serine und ihre Herstellung. Deutsches Patent P 42 29 877.6.
11. Ozaki, S., Y. Watanabe, T. Hoshiko, T. Nagase, T. Ogasawara, H. Furukawa, A. Uemura, K. Ishikawa, H. Mori, and A. Hoshi. 1986. 5-Fluorouracil derivatives. X. Synthesis and antitumor activities of alpha-alkoxyalkyl-5-fluorouracils. Chem. Pharm. Bull. Tokyo. 34: 150-157.
12. Hong, C. I., A. J. Kirisits, A. Nechaev, D. J. Buchheit, and C. R. West. 1985. Nucleoside conjugates. 6. Synthesis and comparison of antitumor activity of 1-β-D-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols. J. Med. Chem. 28: 171-177.
13. Brachwitz, H., R. Hintsche, P. Langen, and J. Schildt. 1982. Halo lipids. 5. Synthesis, nuclear magnetic-resonance spectra and cytostatic properties of halo analogs of alkyllysophospholipids. Chem. Phys. Lipids. 31: 33-52.
14. Lugovkin, B. P. 1957. Synthesis of esters of 8-caffeinyl-methylphosphonic acid. Zhur. Obshch. Khim. 27: 1524-1526.
15. Morita, T., Y. Okamoto, and H, Sakurai. 1978. A convenient dealkylation of dialkyl phosphonates by chlorotrimethylsilane in the presence of sodium iodide. Tetrahedron Lett. 28: 2523-2526.
16. Comfurius, P., and R. F. A. Zwaal. 1977. The enzymatic synthesis of phosphatidylserine and purification by CM-cellulose column chromatography. Biochim. Biophys. Acta. 488: 36-42.
17. Widmaier, R., G. P. Wildner, G. Papsdorf, and I. Graffi. 1974. Über eine neue, in vitro unbegrenzt wachsende Zellinie, MaTu, von Mamma-Tumorzellen des Menschen. Arch. f. Geschwulstf. 44: 1-10.
18. 2+ concentration in a normal and a breast cancer cell line. Anticancer Res. 14: 1549-1556.
19. Scudiero, D. A., R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J. Currens, D. Seniff, and M. R. Boyd. 1988. Evaluation of a soluble tetrazolium formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48: 4827-4833.
20. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260: 3440-3450.
21. Grever, M. R., S. A. Schepartz, and B. A. Chabner. 1992. The National Cancer Institute: Cancer Drug Discovery and Development Program. Semin. Oncol. 19: 622-638.
22. Gill, D. L., R. T. Waldron, K. E. Ryssikora, C. A. Ufretvincenty, M. N. Graber, C. J. Favre, and A. Alfonso. 1996. Calcium pools, calcium entry, and cell growth. Biosci. Rep. 16: 139-157.
23. Trump, B. F., and I. K. Berezesky. 1995. Calcium-mediated cell injury and cell death. FASEB J. 9: 219-228.
24. ++ concentration by alkylphospho-L-serine analogs: relation to their antiproliferative action. J. Lipid Mediat. Cell Signal. 15: 103-114.
25. Lohmeyer, M., and P. Workman. 1995. Growth arrest vs. direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids. Br. J. Cancer. 72: 277-286.
26. Principe, P., H. Coulomb, J. M. Menchiahuerta, C. Broquet, and P. Braquet. 1994. Synergistic cytotoxic effect of aza-alkylphospholipids in association with chemotherapeutic drugs. J. Lipid Mediat. Cell Signal. 10: 171-173.
27. Noseda, A., M. E. Berens, E. J. Modest, and C. Piantadosi. 1987. Neoplastic cell-inhibition with new ether lipid analogs. Lipids. 22: 878-883.
28. Hofmann, J., F. Überall, L. Posch, K. Maly, D. B. J. Herrmann, and H. Grunicke. 1989. Synergistic enhancement of the antiproliferative activity of cis-diamminedichloro-platinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids. 24: 312-317.
29. Principe, P., H. Coulomb, C. Broquet, and P. Braquet. 1992. Evaluation of combinations of antineoplastic ether phospholipids and chemotherapeutic drugs. Anticancer Drug. 3: 577-587.
30. Herrmann, D. B. J., W. Pahlke, H. G. Opitz, and U. Bicker. 1990. In vivo antitumor activity of ilmofosine. Cancer Treat. Rev. 17: 247-252.